H. LUNDBECK A/S Lundbeck is exploring a new area in neurohormonal dysfunctions by initiating a phase II trial using Lu AG13909 as a potential treatment for Cushing's disease. This marks an important step in Lundbeck's commitment to advancing promising scientific innovations. H. Lundbeck A/S (Lundbeck) is enhancing its research and development in neurohormonal dysfun functions.
A key part of this strategy is the development of Lu AG13909, a first-in-class monoclonal antibody (mAb) that targets the adrenocorticotropic hormone (ACTH). By binding to ACTH with high affinity, Lu AG13909 aims to reduce elevated ACTH levels, potentially providing therapeutic benefits for individuals with neurohormonal dysfunctions. In a recent development, a phase II clinical trial assessing efficacy, safety, and tolerability of Lu AG13909 as a potentially treatment for Cushing's disease, has been initiated.
With the latest initiated trial, Lundbeck is currently investigating Lu AG13909 for two conditions: Cushing's disease and congenital adrenal hyperplasia. These ongoing clinical trials underscore Lundbeck's commitment to innovation and expanding treatment options for people with rare neurohormonal dysfunctions; Lu AG13909: A potential treatment for people with Cushing's disease: Cushing's disease is a serious condition caused by a pituitary adenoma leading to excessive production of ACTH, which in turn stimulates the adrenal glands to produce high levels of cortisol. This hormonal imbalance results in clinical manifestations such as weight gain, fatigue, muscle weakness, hypertension, diabetes, obesity, and can lead to early death.
Lu AG13909, a potential cornerstone in the pharmacological treatment of Cushing's disease, is an antibody designed to target ACTH with high precision thereby neutralising the actions of ACTH. Consequently, Lu AG13909 is expected to reduce pathologically elevated ACTH signaling and thus provide a therapeutic benefit to patients with Cushing's disease. This innovative approach may be a significant step forward in managing the disease.
Congenital adrenal hyperplasia is a rare disorder characterized by an enzyme deficiency which disrupts adrenaloidogenesis leading to cortisol and aldosterone deficiency and consequently increased ACTH levels. The increased ACTH levels stimulate the adrenal glands, leading to adrenal hyperplasia and androgen excess, causing the clinical features of congenital adrenal hyperpl Asia. People with congenital adrenal hyperplia are at risk of adrenal crisis, a life-threatening condition.
The challenge lies in balancing glucocorticoid replacement therapy and controlling hyperandrogenism, with the risk of long-term consequences of glucocorticoid overtreatment.
